Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Ondansetron oral disintegrating tablets for the prevention of postoperative vomiting in children undergoing strabismus surgery

Authors Deborah S Wagner, Virginia Gauger, Devi Chiravuri, Kristin Faust

Published 15 September 2007 Volume 2007:3(4) Pages 691—694

Deborah S Wagner, Virginia Gauger, Devi Chiravuri, Kristin Faust

Department of Anesthesiology, University of Michigan Health System, Ann Arbor, MI, USA

Abstract: Strabismus surgery in pediatric patients is associated with a high incidence of postoperative nausea and vomiting (PONV). Ondansetron disintegrating tablets (ODT), an oral freeze-dried formulation of the 5-HT3 antagonist, are well-tolerated and have been shown to reduce chemotherapy-induced vomiting. The purpose of this study was to assess the efficacy of the ODT in preventing postoperative vomiting (POV) in children undergoing strabismus repair. Healthy children aged 4–12 years of age were administered a 4 mg ODT 30 minutes prior to the induction of general anesthesia. Induction and maintenance of anesthesia were standardized; each child received acetaminophen and ketorolac pre-emptively for analgesia. This study group was compared with a historical control group who received a placebo in previously conducted identical trials of POV. The 35 children included in this study were compared with 31 controls. The incidence and severity of POV and use of rescue antiemetics were significantly lower in children who received ODT compared with placebo (p ≤ 0.001). The acute complete response (ie, no emesis and no rescue antiemetics in 24 hours) was 76% in the ODT group compared with 16% in the controls (p ≤ 0.001). Results suggest that ODT given preoperatively reduces the incidence and severity of POV in children undergoing strabismus surgery.

Keywords: pediatrics, postoperative, vomiting, ondansetron

Download Article [PDF] 

Readers of this article also read:

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Michael J Prematta, Tracy Prematta, Timothy J Craig

Therapeutics and Clinical Risk Management 2008, 4:975-982

Published Date: 10 October 2008

Silent myocardial infarction in women with type II diabetes mellitus and microalbuminuria

Elmir Omerovic, Gerhard Brohall, Markus Müller, Truls Råmunddal, Göran Matejka, et al

Therapeutics and Clinical Risk Management 2008, 4:705-711

Published Date: 8 August 2008

Update on local anesthetics: focus on levobupivacaine

Crina L Burlacu, Donal J Buggy

Therapeutics and Clinical Risk Management 2008, 4:381-392

Published Date: 11 April 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia

Alberto Grossi, Francesca Balestri, Simone Santini

Therapeutics and Clinical Risk Management 2007, 3:269-275

Published Date: 15 May 2007

Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B

Eugene B Kern, David Sherris, Angelos M Stergiou, Laura M Katz, Lisa C Rosenblatt, Jens Ponikau

Therapeutics and Clinical Risk Management 2007, 3:319-325

Published Date: 15 May 2007

Editorial ||FREE PAPER||

Garry Walsh

Therapeutics and Clinical Risk Management 2006, 2:127-128

Published Date: 15 June 2006